BigHat and Anthropic improve two antibody leads in lab tests
BigHat and Anthropic reported an antibody-engineering collaboration on October 27. One Anthropic researcher worked with Claude while BigHat's lab made and tested designs. The collaborators describe work on two antibody leads over about 10 weeks. They report better binding, stability, and resistance to clumping in selected variants.
Verified 12:17 AM PDT · 2 original sources
Both accounts come from interested collaborators, without independent replication reported here. These are laboratory properties of two antibody leads, not evidence that a new medicine works in patients. BigHat also says the team changed how instrument readings were interpreted after unreliable measurements appeared.
Examine the technical report, assay changes, and results from other laboratories. Better lab measurements still need to translate into a drug candidate that can pass later testing.
Audit the story
Original sources
Company claims remain company claims. Follow the reporting and judge the evidence directly.
Continue the edition